首页> 美国卫生研究院文献>International Journal of Biological Sciences >Elevated CD163+/CD68+ Ratio at Tumor Invasive Front is Closely Associated with Aggressive Phenotype and Poor Prognosis in Colorectal Cancer
【2h】

Elevated CD163+/CD68+ Ratio at Tumor Invasive Front is Closely Associated with Aggressive Phenotype and Poor Prognosis in Colorectal Cancer

机译:大肠癌中肿瘤侵袭性前沿的CD163 + / CD68 +比值升高与攻击性表型和不良预后密切相关

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

>Background: The interaction and crosstalk between tumor-associated macrophages (TAMs) and epithelial-mesenchymal transition (EMT) has been demonstrated to play a critical role in the progression and metastasis of multiple cancers. However, the roles of the M2-polarized TAMs in different tumor location in EMT and prognosis of colorectal cancer (CRC) have not been elucidated. Therefore, the present study was designed to set up a reliable ratio of CD163+/CD68+ to assess M2-polarized TAMs infiltration in the tumor center (TC) and tumor invasive front (TF) and to further evaluate their prognostic value and biological effects on tumor cells in CRC.>Methods: TAMs markers (CD68 and CD163) and EMT markers (E-cadherin and Vimentin) expression were evaluated by immunohistochemistry in 81 patients with CRC. Circulating tumor cells (CTCs) of peripheral blood from above patients was also isolated. The correlation of CD163+/CD68+ ratio in different locations, EMT and CTCs counts were further analyses. Kaplan-Meier and the model analyses of univariate Cox proportional hazards were utilized to compare the survival of patients with high CD163+/CD68+ ratio with those with low CD163+/CD68+ ratio. Furthermore, the effects of the M2-polarized TAMs on growth, migration and invasion of CRC cells were explored in vivo and in vitro co-culture system.>Results: The results showed that the level of CD163+/CD68+ ratio in TF was significant higher than that in TC, and higher CD163+/CD68+TF ratio were closely correlated with enhanced lymphovascular invasion, tumor invasion and TNM stage. Interestingly, higher CD163+/CD68+TF ratio were also significantly associated with EMT program and CTCs counts. Meanwhile, Kaplan-Meier analysis showed that CD163+/CD68+TF was associated with both recurrence-free survival (RFS) and overall survival (OS) of patients with CRC. Multivariate Cox regression analyses demonstrated that CD163+/CD68+TF remained an independent prognostic factor for RFS and OS. Further receiver operating characteristic (ROC) curve analysis found that CD163+/CD68+TF was a better prognosticator compared with CD68+TF and CD163+TF for CRC patients. What's more, M2-polarized TAMs secreted TGF-β to facilitate the EMT, growth, proliferation and invasion of CRC cells by in vivo and in vitro experiments.>Conclusions: Our studies preliminarily elucidated the prognostic value of CD163+/CD68+ ratio in different tumor locations and the biological functions of M2-polarized TAMs in CRC progression via TGF-β.
机译:>背景:已证明肿瘤相关巨噬细胞(TAM)与上皮间质转化(EMT)之间的相互作用和串扰在多种癌症的进展和转移中起着至关重要的作用。然而,尚未阐明M2极化的TAM在EMT中不同肿瘤位置和大肠癌(CRC)预后中的作用。因此,本研究旨在建立可靠的CD163 + / CD68 + 比率,以评估M2极化的TAM在肿瘤中心(TC)和肿瘤浸润中的浸润情况>方法:通过TAMs标记(CD68和CD163)和EMT标记(E-cadherin和Vimentin)的表达来评估CRC的预后价值和生物学效应。 81例CRC患者的免疫组织化学。还分离了来自上述患者的外周血循环肿瘤细胞(CTC)。进一步分析了不同部位CD163 + / CD68 + 比值,EMT和CTCs的相关性。用Kaplan-Meier和单变量Cox比例风险模型分析比较CD163 + / CD68 + 高比率和CD163 低的患者的生存率+ / CD68 + 比率。此外,在体内和体外共培养系统中,研究了M2极化的TAMs对CRC细胞生长,迁移和侵袭的影响。>结果:结果表明,CD163 + / CD68 + 比显着高于TC,而CD163 + / CD68 + TF比更高与淋巴管浸润增强,肿瘤浸润和TNM分期密切相关。有趣的是,较高的CD163 + / CD68 + TF比值也与EMT程序和CTC计数显着相关。同时,Kaplan-Meier分析显示CD163 + / CD68 + TF与CRC患者的无复发生存期(RFS)和总体生存期(OS)相关。多变量Cox回归分析表明,CD163 + / CD68 + TF仍然是RFS和OS的独立预后因素。进一步的受试者工作特征曲线分析发现,与CD68 + TF和CD163 <相比,CD163 + / CD68 + TF是更好的预后指标。 sup> + TF用于CRC患者。此外,通过体内和体外实验,M2极化的TAM分泌TGF-β促进CRC细胞的EMT,生长,增殖和侵袭。>结论:我们的研究初步阐明了CD163的预后价值不同肿瘤部位的 + / CD68 + 比率以及M2极化的TAMs通过TGF-β在CRC进展中的生物学功能。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号